Formulation and Evaluation Xylometazoline Hydrochloride Mucoadhesive Nasal in Situ Gel
Main Article Content
Abstract
The objective of research is to develop a mucoadhesive in-situ nasal gel formulation of xylometazoline hydrochloride for the treatment of allergic rhinitis to avoid possible side effects. Mucoadhesive in-situ nasal gel of xylometazoline hydrochloride was formulated by ionic gelation method using xanthan gum as ionsensitive agent and different grades of HPMC as a viscosifying agent. The prepared batches were evaluated for drug content, pH, gelling time, spreadability, gelling strength, mucoadhesive strength and in-vitro drug release. In vitro drug release study was carried by using diffusion cell with dialysis membrane. Short term stability study was also performed for final formulation as per ICH guidelines. The drug content and pH of the formulation were found to be satisfactory. The mucoadhesive strength of the formulation was found to be from 212.55 gm/cm2 to 490.8 gm/cm2. The viscosity and spredability of the formulations were found to be satisfactory. Amongst all these formulations, the maximum drug release was found to be 81.46 % in formulation F8 containing 0.2 % xanthan gum and 0.5 % HPMC K15M . The developed formulations showed sustained release of drug up to 8 hrs and found to be stable.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Mundlia J and Kumar M, “Nasal drug delivery- an overview.” International journal of pharmaceutical science and research. 2015; Vol.6(3):951-960.
II. Muhammad UG, Mohammed HA, Alan MS and Barbara RC, “Nasal drug delivery system: an overview,” Indo American journal of pharmacy.2015; Vol.3(5), 110-119.
III. Chavan PV and Vyas S, “A novel approach in-situ gel for sustained drug delivery: a Review,” International Journal of Pharmacy and Pharmaceutical Research.2017; Vol.9(4), 260-280.
IV. Golander Y and Dewritte WJ, “Xylometazoline hydrochloride,” Analytical Profile of Drug Substance .1985; Vol 14, 135-156.
V. Ban MM, Chakote VR, Dhembre GN, Rajguru JR and Joshi DA, “In-situ gel for nasal drug delivery,” International Journal of Development Research. 2018; Vol.8(2), 18763-18769.
VI. Parekh HB, “Novel in situ polymeric drug delivery system: a review,” Journal of drug delivery and therapeutics. 2012; Vol.2 (5), 136-145.
VII. Manaka M, Pandey VP and Anton AS, “Formulation development and evaluation of ondensetron hydrochloride nasal spray,” International Journal of pharmacy and pharmaceutical sciences. 2013; Vol.5 (4), 150-154.
VIII. Nirmal HB, Bakliwal SR and Pawar SP, “In-situ gel: new trend in controlled and sustained drug delivery system,” International journal of pharmatech research. 2010; Vol.2 (2), 1398-1408.
IX. Paul A, Fathima KM and Nair SC, “Intra nasal in situ gelling system of lamotrigine using ion activated mucoadhesive polymer,” Open Journal of Medicinal Chemistry. 2017; Vol.11, 222-244.
X. Ahmed VA and Goli D, “Xyloglucan based in-situ gel: formulation development and evaluation of in-situ ophthalmic gel of brimonidine tartrate,” Indo Global Journal of Pharmaceutical Science. 2018; Vol.8 (3), 92-103.
XI. Godbole MD, There PW and Dangre PV, “Formulation and optimization of prolonged released nasal in-situ gel for treatment of migraine,” Indo American Journal of Pharmacy. 2014; Vol.4 (2), 1320-1332.
XII. Valavi MP, Tadavi SA, Shaikh A and Pawar SP, “Review on insitu gel a novel drug delivery system,” World Journal of Pharmacy and Pharmaceutical science. 2019; Vol.8 (2), 1288-1309.
XIII. Ranch K, Patel H, Chavda L., Koli A, Maulvi F, Parikh RK, “ Development of in situ ophthalmic gel of dexamethasone sodium phosphate and chloramphenicol: a viable alternative to conventional eye drops, “ Journal of Applied pharmaceutical science 2017; Vol.7 (3), 101-108.
XIV. Galgatte UC, Kumbhar AB and Chaudhari PD, “Development of in situ gel for nasal delivery: design, optimization, in vitro and in vivo evaluation,” Drug Delivery. 2014; Vol.21 (1), 62-73.
XV. Gupta C, Juyal V, Nagaich U, “Formulation, optimization, and evaluation of in-situ gel of moxifloxacin hydrochloride for ophthalmic drug delivery,” International Journal of applied pharmaceutics - 2019.